Limited role of KRAS mutation in guiding immunotherapy in advanced non-small-cell lung cancer

Autor:	Hong-Shuai Li, Cheng-Ming Liu, Yan Wang
Rok vydání:	2022
Předmět:	Cancer Research Oncology General Medicine
Zdroj:	Future Oncology. 18:2433-2443
ISSN:	1744-8301 1479-6694
DOI:	10.2217/fon-2021-1488
Popis:	The success of sotorasib (AMG-510) and adagrasib (MRTX-849) has resolved the problem of non-availability of drugs for patients with KRASG12C-mutated non-small-cell lung cancer. However, more research is required before these drugs can be introduced as a first-line treatment for those patients, and there are no available drugs for other non-G12C-mutated patients so far; therefore, immunotherapy remains the optimal first-line treatment in this situation. The role of KRAS in affecting the response to immunotherapy in non-small-cell lung cancer has not been fully elucidated. The purpose of this review was to summarize the impact of KRAS mutations, a highly heterogeneous group, on immunotherapy to provide clinicians and researchers with relevant information that can help guide decision-making.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::aeca3e0314c4bad6b4b7ab417f5beec0 https://doi.org/10.2217/fon-2021-1488 Zobrazit plný text záznamu